Other Consolidated Financial Statement Detail (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Prepaid taxes		$ 280,500		$ 280,500		$ 57,600
Accrued Expenses and Other
Current portion of contingent consideration obligations		493,500		493,500		265,500
Revenue-related rebates		590,400		590,400		483,800
Employee compensation and benefits		214,400		214,400		393,800
Royalties and licensing fees		161,900		161,900		172,400
Deferred revenue		62,500		62,500		120,900
Other		433,300		433,300		507,500
Total accrued expenses and other		1,812,099		1,812,099		1,819,334
Other Income (Expense), Net
Interest income		4,300	$ 2,400	7,600	$ 5,100
Interest expense		(5,800)	(7,100)	(12,500)	(14,700)
Gain (loss) on sales of investments, net		300	13,600	(1,400)	16,600
Foreign exchange gains (losses), net		(1,500)	(1,400)	(14,500)	(4,700)
Other, net		(8,200)	(2,600)	(5,100)	(3,000)
Business Acquisition [Line Items]
Contingent consideration		36,000	0	274,500	0
Other income (expense), net		(10,889)	$ 4,861	(25,875)	$ (740)
Liabilities, Noncurrent
Contingent consideration obligations		302,200		302,200		200,000
Employee related liabilities noncurrent		224,500		224,500		200,700
Other		389,000		389,000		249,400
Total other long-term liabilities		915,731		915,731		650,096
Convergence Pharmaceuticals
Business Acquisition [Line Items]
Cash portion of consideration	$ 200,100
Contingent consideration	274,500
Total purchase price	$ 474,600
Component of accrued expenses and other
Accrued Expenses and Other
Revenue-related rebates		$ 446,500		$ 446,500		$ 359,200